Gastrointestinal immune-related adverse events (irAEs) are the most common AEs that lead to hospital admissions and readmissions in patients with genitourinary cancers prescribed immune checkpoint therapies, according to a new study presented at the 2025 ASCO Genitourinary Cancers Symposium (abstract 462).
In the study, researchers at The University of Texas MD Anderson Cancer Center analyzed patients admitted to the center’s genitourinary medical oncology inpatient service between June